Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

DISEASE CHARACTERISTICS:

Histologically confirmed diagnosis of 1 of the following:

Neuroblastoma
Rhabdomyosarcoma
Wilms tumor
Retinoblastoma
Adrenocortical carcinoma
Carcinoid tumor
Relapsed or refractory disease
Measurable or evaluable disease
No known curative therapy or therapy proven to prolong survival with an acceptable quality of life
No known pulmonary tumors or metastases > 5 cm, as evaluated by chest CT scan
No clinically significant pulmonary and/or pericardial effusions (≥ grade 3), as evaluated by ECHO
No primary CNS tumors or known metastatic CNS disease involvement

PATIENT CHARACTERISTICS:

Karnofsky performance status (PS) 50-100% (for patients > 16 years of age)
Lansky PS 50-100% (for patients ≤ 16 years of age)
Peripheral ANC ≥ 1,000/mm^3
Platelet count ≥ 100,000/mm^3 (transfusion independent, defined as no platelet transfusions within a 7-day period before study enrollment)
Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)

Creatine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age/gender as follows:

≤ 0.8 mg/dL (for patients 3 to 5 years of age)
≤ 1.0 mg/dL (for patients 6 to 9 years of age)
≤ 1.2 mg/dL (for patients 10 to 12 years of age)
≤ 1.4 mg/dL (for female patients ≥ 13 years of age)
≤ 1.5 mg/dL (for male patients 13 to 15 years of age)
≤ 1.7 mg/dL (for male patients ≥ 16 years of age)
Bilirubin (sum of conjugated and unconjugated) ≤ 1.5 times upper limit of normal (ULN)
SGPT ≤ 110 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L)
Serum albumin ≥ 2 g/dL
Oxygen saturation > 92% on room air
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Able to comply with the safety monitoring requirements of the study, in the opinion of the investigator
Completely toilet trained
No chronic diarrhea or urinary incontinence during the day or night, , and no in-dwellling urinary catheters
No uncontrolled infection
No known pregnant member of the household

PRIOR CONCURRENT THERAPY:

Fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy
At least 6 months since prior total-body irradiation (TBI), craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis

At least 3 months since prior stem cell transplantation or rescue (without TBI)

No evidence of active graft-vs-host disease
At least 6 weeks since other prior substantial bone marrow radiotherapy or treatment with therapeutic doses of MIBG
More than 3 weeks since prior myelosuppressive chemotherapy
At least 2 weeks since prior local palliative radiotherapy (small port)
More than 7 days since prior growth factor(s) that support platelet or white blood cell number or function
At least 7 days since prior biologic agents
At least 3 half-lives since prior monoclonal antibodies
More than 7 days since prior viral immunizations, including influenza
At least 42 days since the completion of any type of immunotherapy, e.g., tumor vaccines
No other viral immunizations after enrolling on study until 28 days after their last planned Seneca Valley virus-001 infusion or until documented viral clearance, whichever is longest
Concurrent corticosteroids allowed provided the patient has been on a stable or decreasing dose for the past 7 days
No other concurrent investigational drugs
No other concurrent anticancer agents (e.g., chemotherapy, radiotherapy, immunotherapy, or biologic therapy)
Prior treatment with Seneca Valley virus-001 is not allowed